Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PRFX vs PCRX vs PRGO vs BHC vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PRFX
PainReform Ltd.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • IL
Market Cap$862K
5Y Perf.-99.9%
PCRX
Pacira BioSciences, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$930M
5Y Perf.-61.5%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-74.5%
BHC
Bausch Health Companies Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • CA
Market Cap$2.14B
5Y Perf.-63.0%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+394.5%

PRFX vs PCRX vs PRGO vs BHC vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PRFX logoPRFX
PCRX logoPCRX
PRGO logoPRGO
BHC logoBHC
MCK logoMCK
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$862K$930M$1.61B$2.14B$92.15B
Revenue (TTM)$0.00$735M$4.18B$10.55B$403.43B
Net Income (TTM)$-4M$9M$-1.82B$-1.19B$4.76B
Gross Margin60.2%34.2%61.7%3.6%
Operating Margin3.4%-4.1%22.9%1.5%
Forward P/E8.1x5.5x1.3x16.7x
Total Debt$45K$454M$3.97B$21.21B$7.39B
Cash & Equiv.$4M$159M$532M$1.32B$5.69B

PRFX vs PCRX vs PRGO vs BHC vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PRFX
PCRX
PRGO
BHC
MCK
StockSep 20May 26Return
PainReform Ltd. (PRFX)1000.1-99.9%
Pacira BioSciences,… (PCRX)10038.5-61.5%
Perrigo Company plc (PRGO)10025.5-74.5%
Bausch Health Compa… (BHC)10037.0-63.0%
McKesson Corporation (MCK)100494.5+394.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: PRFX vs PCRX vs PRGO vs BHC vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PRFX and BHC are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Bausch Health Companies Inc. is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. MCK and PRGO also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PRFX
PainReform Ltd.
The Growth Leader

PRFX has the current edge in this matchup, primarily because of its strength in growth and quality.

  • 77.9% revenue growth vs PRGO's -2.8%
  • 1.9% margin vs PRGO's -43.5%
Best for: growth and quality
PCRX
Pacira BioSciences, Inc.
The Defensive Pick

PCRX is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.47, Low D/E 65.6%, current ratio 4.54x
Best for: sleep-well-at-night
PRGO
Perrigo Company plc
The Defensive Pick

PRGO is the clearest fit if your priority is defensive.

  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Best for: defensive
BHC
Bausch Health Companies Inc.
The Growth Play

BHC is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 8.5%, EPS growth 430.8%, 3Y rev CAGR 8.7%
  • Lower P/E (1.3x vs 16.7x)
  • +21.8% vs PRFX's -82.1%
Best for: growth exposure
MCK
McKesson Corporation
The Income Pick

MCK ranks third and is worth considering specifically for income & stability and long-term compounding.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 348.1% 10Y total return vs PCRX's -51.2%
  • Beta 0.04 vs PRFX's 1.73
  • 5.7% ROA vs PRFX's -36.6%
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthPRFX logoPRFX77.9% revenue growth vs PRGO's -2.8%
ValueBHC logoBHCLower P/E (1.3x vs 16.7x)
Quality / MarginsPRFX logoPRFX1.9% margin vs PRGO's -43.5%
Stability / SafetyMCK logoMCKBeta 0.04 vs PRFX's 1.73
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Momentum (1Y)BHC logoBHC+21.8% vs PRFX's -82.1%
Efficiency (ROA)MCK logoMCK5.7% ROA vs PRFX's -36.6%

PRFX vs PCRX vs PRGO vs BHC vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PRFXPainReform Ltd.

Segment breakdown not available.

PCRXPacira BioSciences, Inc.
FY 2025
Product
50.9%$723M
EXPAREL
40.5%$575M
ZILRETTA
8.2%$117M
Bupivacaine Liposome Injectable Suspension
0.5%$7M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
BHCBausch Health Companies Inc.
FY 2025
Product
49.5%$10.2B
Pharmaceutical Products
23.1%$4.7B
Device Products
11.9%$2.4B
Over the Counter Products
9.8%$2.0B
Branded and Other Generic Products
4.7%$962M
Other Revenues
0.5%$110M
Product and Service, Other
0.5%$110M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

PRFX vs PCRX vs PRGO vs BHC vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLBHCLAGGINGPRGO

Income & Cash Flow (Last 12 Months)

BHC leads this category, winning 3 of 6 comparable metrics.

MCK and PRFX operate at a comparable scale, with $403.4B and $0 in trailing revenue. PCRX is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BHC holds the edge at +10.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$0$735M$4.2B$10.6B$403.4B
EBITDAEarnings before interest/tax-$4M$95M$58M$3.6B$6.8B
Net IncomeAfter-tax profit-$4M$9M-$1.8B-$1.2B$4.8B
Free Cash FlowCash after capex-$6M$133M$108M$990M$6.0B
Gross MarginGross profit ÷ Revenue+60.2%+34.2%+61.7%+3.6%
Operating MarginEBIT ÷ Revenue+3.4%-4.1%+22.9%+1.5%
Net MarginNet income ÷ Revenue+1.3%-43.5%-11.3%+1.2%
FCF MarginFCF ÷ Revenue+18.1%+2.6%+9.4%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+5.0%-7.2%+10.5%+6.0%
EPS Growth (YoY)Latest quarter vs prior year+98.9%-30.0%-56.4%-22.7%+37.0%
BHC leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

BHC leads this category, winning 4 of 6 comparable metrics.

At 13.3x trailing earnings, BHC trades at a 91% valuation discount to PCRX's 147.8x P/E. On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than MCK's 18.7x.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
Market CapShares × price$861,734$930M$1.6B$2.1B$92.1B
Enterprise ValueMkt cap + debt − cash-$3M$1.2B$5.1B$22.0B$93.8B
Trailing P/EPrice ÷ TTM EPS-0.06x147.75x-1.14x13.31x29.25x
Forward P/EPrice ÷ next-FY EPS est.8.13x5.53x1.33x16.66x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple9.86x7.42x6.38x18.74x
Price / SalesMarket cap ÷ Revenue1.28x0.38x0.20x0.26x
Price / BookPrice ÷ Book value/share0.47x1.54x0.55x5.71x
Price / FCFMarket cap ÷ FCF6.80x11.12x2.13x17.63x
BHC leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 4 of 9 comparable metrics.

BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for PRGO. PRFX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), PCRX scores 9/9 vs PRFX's 1/9, reflecting strong financial health.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-48.4%+1.3%-50.7%+5.9%+3.0%
ROA (TTM)Return on assets-36.6%+0.7%-19.8%-4.5%+5.7%
ROICReturn on invested capital+2.3%+3.7%+8.2%+5.4%
ROCEReturn on capital employed-3.1%+2.8%+4.3%+10.6%+30.5%
Piotroski ScoreFundamental quality 0–919476
Debt / EquityFinancial leverage0.02x0.66x1.35x56.36x
Net DebtTotal debt minus cash-$4M$296M$3.4B$19.9B$1.7B
Cash & Equiv.Liquid assets$4M$159M$532M$1.3B$5.7B
Total DebtShort + long-term debt$45,000$454M$4.0B$21.2B$7.4B
Interest CoverageEBIT ÷ Interest expense-1048.07x2.37x-7.20x1.43x33.79x
MCK leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $23 for PRFX. Over the past 12 months, BHC leads with a +21.8% total return vs PRFX's -82.1%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs PRFX's -78.7% — a key indicator of consistent wealth creation.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-45.6%-3.4%-13.5%-20.6%-8.5%
1-Year ReturnPast 12 months-82.1%-6.1%-51.2%+21.8%+4.6%
3-Year ReturnCumulative with dividends-99.0%-44.1%-58.1%-4.4%+106.4%
5-Year ReturnCumulative with dividends-99.8%-62.6%-60.1%-79.6%+286.9%
10-Year ReturnCumulative with dividends-99.9%-51.2%-77.7%-79.6%+348.1%
CAGR (3Y)Annualised 3-year return-78.7%-17.6%-25.2%-1.5%+27.3%
MCK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PCRX and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than PRFX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PCRX currently trades 85.5% from its 52-week high vs PRFX's 10.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.69x0.41x1.21x0.96x-0.02x
52-Week HighHighest price in past year$17.95$27.64$28.44$8.69$999.00
52-Week LowLowest price in past year$0.77$18.80$9.23$4.41$637.00
% of 52W HighCurrent price vs 52-week peak+10.6%+85.5%+41.2%+65.9%+75.3%
RSI (14)Momentum oscillator 0–10035.045.960.952.316.2
Avg Volume (50D)Average daily shares traded622K695K3.4M1.8M757K
Evenly matched — PCRX and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: PCRX as "Hold", PRGO as "Hold", BHC as "Buy", MCK as "Buy". Consensus price targets imply 208.9% upside for PRGO (target: $36) vs 24.8% for PCRX (target: $30). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricPRFX logoPRFXPainReform Ltd.PCRX logoPCRXPacira BioScience…PRGO logoPRGOPerrigo Company p…BHC logoBHCBausch Health Com…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellHoldHoldBuyBuy
Price TargetConsensus 12-month target$29.50$36.20$8.00$994.86
# AnalystsCovering analysts36363831
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%
Dividend StreakConsecutive years of raises10217
Dividend / ShareAnnual DPS$1.15$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%+16.0%0.0%0.0%+3.4%
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

BHC leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). MCK leads in 2 (Profitability & Efficiency, Total Returns). 2 tied.

Best OverallBausch Health Companies Inc. (BHC)Leads 2 of 6 categories
Loading custom metrics...

PRFX vs PCRX vs PRGO vs BHC vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PRFX or PCRX or PRGO or BHC or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 3x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PRFX or PCRX or PRGO or BHC or MCK?

On trailing P/E, Bausch Health Companies Inc.

(BHC) is the cheapest at 13. 3x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x.

03

Which is the better long-term investment — PRFX or PCRX or PRGO or BHC or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -99. 8% for PainReform Ltd. (PRFX). Over 10 years, the gap is even starker: MCK returned +339. 0% versus PRFX's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PRFX or PCRX or PRGO or BHC or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus PainReform Ltd. 's 1. 69β — meaning PRFX is approximately -10402% more volatile than MCK relative to the S&P 500. On balance sheet safety, PainReform Ltd. (PRFX) carries a lower debt/equity ratio of 2% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PRFX or PCRX or PRGO or BHC or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PRFX or PCRX or PRGO or BHC or MCK?

Bausch Health Companies Inc.

(BHC) is the more profitable company, earning 1. 5% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BHC leads at 21. 3% versus 0. 0% for PRFX. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PRFX or PCRX or PRGO or BHC or MCK more undervalued right now?

On forward earnings alone, Bausch Health Companies Inc.

(BHC) trades at 1. 3x forward P/E versus 16. 7x for McKesson Corporation — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

08

Which pays a better dividend — PRFX or PCRX or PRGO or BHC or MCK?

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. PRFX, PCRX, BHC do not pay a meaningful dividend and should not be held primarily for income.

09

Is PRFX or PCRX or PRGO or BHC or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). PainReform Ltd. (PRFX) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +339. 0%, PRFX: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PRFX and PCRX and PRGO and BHC and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRFX is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; BHC is a small-cap deep-value stock; MCK is a mid-cap high-growth stock. PRGO pays a dividend while PRFX, PCRX, BHC, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PRFX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

PCRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 36%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

BHC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 37%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.